Cardiovascular Drugs for Liver Disease Treatment

Summary of Research on Pemafibrate & Telmisartan for Metabolic Liver Disease (MASLD)

This research, published in pharmacological Research, investigates the potential of repurposing existing drugs – pemafibrate (a lipid-lowering drug) and telmisartan (an antihypertensive) – to treat Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as fatty liver disease.

Key Findings:

* Effective Fat Reduction: Both drugs, and especially the combination ‍ of the two,⁣ effectively reduced fat accumulation in laboratory animal models (rats and zebrafish larvae) of MASLD.
* Potential for Reduced Complications: The study suggests the combination may help reduce both liver involvement and associated cardiovascular complications, which are a significant concern for MASLD patients.
* Synergistic Effect & Lower Doses: Combining half doses of each drug was as effective as full doses of either drug alone,suggesting a synergistic effect and potential for reduced toxicity.
* Drug Repurposing ‍is Promising: ⁤Repurposing existing drugs ⁣with known safety profiles is a cost-effective and‍ safer strategy than developing new compounds, especially⁣ for early-stage MASLD treatment.
* Focus on Early Stages: The research focuses on preventing disease progression‍ in the early, often asymptomatic, stages of MASLD.

Study Details:

* Researchers: ⁢ Led by marta Alegret (University of Barcelona, IBUB, CIBEROBN) with collaboration from multiple institutions in Spain and Sweden.
* Models Used: rat model and zebrafish larvae model (zebrafish offer a faster, cheaper, and physiologically relevant alternative).
* rationale: MASLD patients often have cardiovascular risk factors like hyperlipidaemia and hypertension, which pemafibrate and telmisartan respectively treat.

the study offers a promising avenue for developing safer and more effective treatments for MASLD,⁣ especially by leveraging existing drugs and‍ focusing⁤ on early intervention.